Amicus Therapeutics, Inc. (FOLD) Valuation According To Analysts

Marco Green
September 14, 2017

Argan Inc now has $953.61 million valuation. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell. About 63,926 shares traded. HSBC Holdings plc (ADR) (NYSE:HSBC) has risen 38.28% since September 13, 2016 and is uptrending. It has outperformed by 80.48% the S&P500. The stock appeared $66.13 above its 52-week highs and is up 4.07% for the last five trades. Its down 4.39% from 35.19M shares previously.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) ended its day at $13.67 with the rising stream of -1.30% and its total traded volume was 2.77 million shares less than the average volume. The SI to Hsbc Holdings Plc's float is 0.1%. The company had a trading volume of 11,511,538 shares.

Amicus Therapeutics, Inc. (NASDAQ:FOLD), maintained return on investment for the last twelve months at -, higher than what Reuters data shows regarding industry's average. It has underperformed by 4.25% the S&P500.

When the trading finished on 09/12/2017 Amicus Therapeutics, Inc. Therefore 89% are positive.

For the Current Quarter, the growth estimate for Amicus Therapeutics, -12.1%, while for the Next Quarter the stock growth estimate is 31%.

03/30/2017 - Amicus Therapeutics, Inc. had its "outperform" rating reiterated by analysts at Leerink Swann.

Stock of Amicus Therapeutics, Inc. The company was initiated on Thursday, April 14 by Robert W. Baird. The rating was upgraded by Robert W. Baird on Tuesday, January 24 to "Outperform". (NYSE:AGX) has "Buy" rating given on Thursday, June 9 by Lake Street.

05/24/2017 - Amicus Therapeutics, Inc. had its "buy" rating reiterated by analysts at Bank of America Merrill Lynch. (NASDAQ:FOLD) or 30,000 shares. California State Teachers Retirement System invested 0% in Amicus Therapeutics, Inc. JP Morgan maintained Amicus Therapeutics, Inc. The stock's market capitalization is 2.22B. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. It now has negative earnings. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Investors sentiment increased to 1.23 in Q4 2016. They expect this year's earnings to fall -0.72% year-over-year to -$1.38, followed by -18.84% decline in the next year to -$1.12. Trims Stake in Amicus Therapeutics, Inc. $239,312 worth of Amicus Therapeutics, Inc. Highland Mgmt Limited Partnership invested in 0.01% or 38,000 shares. 184,929 are owned by Credit Suisse Ag.

On a similar note, analysts expect EPS of -$0.39 in September 2017 quarter and -$0.28 in December 2017 quarter, representing 18.18% and -12.5% growth, respectively. Amer Int Group reported 73,233 shares or 0% of all its holdings. (NASDAQ:FOLD). Proshare Advisors Lc reported 0.01% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Ubs Asset Management Americas invested in 0% or 29,500 shares. State Board Of Administration Of Florida Retirement System reported 55,248 shares stake.

Since May 15, 2017, it had 0 buys, and 3 insider sales for $778,624 activity. On Monday, March 27 ADAIR A JAYSON sold $12.41 million worth of Copart, Inc. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Therefore 68% are positive. (NASDAQ:CPRT) has "Hold" rating given on Thursday, July 6 by Jefferies. The firm earned "Hold" rating on Wednesday, June 28 by Stifel Nicolaus. The rating was upgraded by Chardan Capital Markets to "Buy" on Monday, October 5. Chardan Capital Markets downgraded the stock to "Neutral" rating in Wednesday, September 16 report. On Wednesday, September 14 the stock rating was downgraded by UBS to "Neutral".

Opus Investment Management Inc increased Mcdonald's Corp. Axa reported 2.17 million shares. It also reduced Agile Therapeutics (NASDAQ:AGRX) stake by 358,565 shares and now owns 661,446 shares. Lyondellbasell Ind Nv (NYSE:NJR) was raised too.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Other reports by Click Lancashire

Discuss This Article